Understanding The Basics Of Microdosing: What It Is, How It Works, And What The Research Shows
- Anahita Anais
- May 13, 2025
- 7 min read
Updated: Jun 16
By Anahita Anais, Microdosing and Nervous System Expert, founder of Microdose Guru.
This article is educational and is not medical advice. Microdosing involves Schedule I substances and carries real risks. Talk to a qualified healthcare provider before you start, especially if you take medication or have a mental health condition.
Last updated: June 2026.
Microdosing has moved from the fringe into ordinary conversation. People take small amounts of a psychedelic, far below the level that produces a noticeable effect, hoping for steadier mood, sharper focus, or more creativity in daily life. This page covers the foundations: what a microdose is, where the practice comes from, the most common schedules people follow, and what the evidence does and does not support. For how to find your own dose within a safe range, see the dedicated guide linked below.
The Basics Of Microdosing
What Microdosing Means
A true microdose is sub-perceptual. You should not feel high, see anything shift, or lose any function. If you do, the dose was too large for microdosing.
The two substances most people use are dried psilocybin mushrooms and LSD. The canonical ranges:
Dried cubensis mushrooms: roughly 0.05 to 0.30 g (50 to 300 mg) per dose.
LSD: roughly 5 to 20 micrograms (µg) per dose. Note the unit. LSD is dosed in micrograms, never milligrams; a milligram dose would be a serious overdose.
Start at the low end and adjust slowly. A common mistake is treating a mini or perceptual dose as a microdose, which is how people end up unexpectedly altered during a workday. For a plain breakdown of weights, units, and what a starting dose looks like, see how much is a microdose.
These substances did not appear in a lab. Psilocybin mushrooms have been used in Indigenous and ceremonial contexts for centuries, most prominently by Mazatec communities in Oaxaca, Mexico. The modern wellness framing of "microdosing" is recent; the plants and practices behind it are not, and they deserve to be named rather than erased.
A Quick Note Before The Dosing Details
This is the right place to repeat it: microdosing is educational territory here, not a prescription. If you take an SSRI, SNRI, MAOI, lithium, or another psychiatric medication, do not start without talking to your prescriber first. The interactions at microdose levels are poorly studied, and combining classic psychedelics with lithium in particular is a known harm-reduction red line. There is more on the medication question in can I microdose if I'm taking antidepressants, and more on contraindications below.
Common Microdosing Schedules
Most people follow a fixed schedule rather than dosing daily, partly to limit tolerance. Two named protocols come up most often.
The Fadiman protocol: Popularized by psychologist James Fadiman in his 2011 book The Psychedelic Explorer's Guide, this is a one-day-on, two-days-off cycle: dose on day one, then take days two and three off before dosing again. Fadiman's reasoning is that some effect can carry into the day after a dose, and the rest days let you return to baseline before the next one.
The Stamets stack: Named for mycologist Paul Stamets, this combines a psilocybin microdose with Lion's Mane mushroom and niacin (vitamin B3), typically on a several-days-on, few-days-off cycle. Stamets has proposed that the combination supports the growth of new neural connections. It is worth being precise here: the neurogenesis idea rests on Stamets's own hypothesis and on animal studies, not on confirmed human results, so treat it as a theory people find compelling rather than an established fact. The Stamets stack has its own dedicated guide.
Whatever schedule you use, what you put around it matters too. Keeping a simple written record of dose, day, and how you felt helps you work from your own data rather than memory, and it makes any adjustment a deliberate choice rather than a guess.
The Research
Here is the honest state of the evidence. Microdosing is genuinely under-studied, and the most rigorous results complicate the popular story.
Early observational work found reasons for interest. In a six-week study of 98 microdosers, participants reported reductions in depression and stress and lower distractibility, alongside some less favorable changes (Polito & Stevenson, PLOS ONE, 2019). A larger observational study following more than 950 microdosers found greater self-reported improvements in mood and mental health at one month compared with non-microdosing controls (Rootman et al., Scientific Reports, 2022).
But observational studies cannot separate a drug effect from expectation. The most important test of that is a self-blinding, placebo-controlled citizen-science study of 191 participants. People taking the real microdose and people unknowingly taking a placebo both improved, and the difference between the groups was not significant. The authors concluded that much of the reported benefit may be explained by the placebo effect (Szigeti et al., eLife, 2021).
The controlled evidence has only gotten less flattering since. A 2025 Neuropharmacology report pooling two double-blind, placebo-controlled longitudinal trials of psilocybin microdosing found that microdosing did not reliably affect cognitive or subjective measures compared with placebo. A few early signals in social cognition, mood, and self-reported cognitive flexibility did not survive correction for multiple comparisons, and participants stayed effectively blinded throughout, so the null result was not a blinding failure (Neuropharmacology, 2025). A 2024 review of the controlled literature reached the same place: of the placebo-controlled microdosing studies done to date, most are on LSD, only a couple are on psilocybin, and the effects that show up are subtle at best (Murphy et al., Biological Psychiatry: CNNI, 2024).
A note on what is not being measured here. The headlines about psilocybin you may have seen in 2025 and 2026 are about full therapeutic doses given under supervision, not microdoses. Compass Pathways reported positive results in two Phase 3 trials of a 25 mg psilocybin dose for treatment-resistant depression, in June 2025 and again in February 2026, and has said it is moving toward an FDA submission (Compass Pathways, Feb 2026). In April 2026 the FDA granted breakthrough designations to psilocybin-related compounds and signaled faster review of psychedelic mental-health drugs (CNN, Apr 2026). None of that is evidence that microdosing works. A 25 mg supervised session and a 0.10 g dose taken to stay functional at your desk are different interventions, and the regulatory momentum belongs to the former.
So the fair summary is this: some people who microdose report better mood, focus, and creativity, but the controlled findings are mixed to null, and the strongest evidence points heavily toward expectation as a driver. The field is young. Treat anyone who tells you the benefits are settled science with skepticism.
Risks And Who Should Not Microdose
Both psilocybin and LSD are Schedule I substances under the U.S. Controlled Substances Act, meaning they have no federally accepted medical use and possession is illegal in most places (DEA / Controlled Substances Act). The 2025 and 2026 trial results above have not changed that legal status; psilocybin remains Schedule I while it works through the approval process. That status also means quality and dosing of what people obtain are unregulated and inconsistent, which is its own hazard.
Beyond legality, classic psychedelics are not safe for everyone. Clinical trials routinely exclude people with a personal or family history of psychosis, schizophrenia, or bipolar disorder because of the risk of triggering mania or a psychotic episode. People on lithium should not combine it with psychedelics. Interactions with SSRIs and other psychiatric medications at microdose levels remain largely unstudied, which is a reason for caution, not reassurance (NCCIH, "Psilocybin for Mental Health and Addiction"). This is exactly why the prescriber conversation comes first. For a fuller look at where the real dangers sit, see Can Microdosing Be Dangerous.
Frequently Asked Questions
Is Microdosing Legal?
In most of the United States and most countries, no. Psilocybin and LSD are Schedule I, so possession is illegal in the majority of jurisdictions, with a small number of local exceptions. The positive psilocybin trials moving through the FDA in 2025 and 2026 are for supervised therapeutic use and have not changed the legal status of buying or possessing these substances on your own.
How Is A Microdose Different From A Regular Dose?
By size and intent. A microdose is sub-perceptual, roughly 0.05 to 0.30 g of dried cubensis or 5 to 20 µg of LSD, taken so you can carry on with an ordinary day. A full or "macro" dose is many times larger and produces a clear psychedelic experience. The depression trials in the news use full supervised doses, not microdoses.
Does Microdosing Work?
The honest answer is that the controlled evidence is weak. Observational surveys are positive, but double-blind, placebo-controlled studies, including a 2025 pooled analysis, mostly find no significant difference from placebo. People who feel a benefit are not imagining it, but expectation appears to explain much of it.
Which Schedule Should A Beginner Use?
The Fadiman protocol (one day on, two days off) is the most common starting point because the rest days limit tolerance and let you return to baseline. The Stamets stack is the other well-known option. Neither is medically endorsed, and any schedule should follow a conversation with your prescriber if you take medication.
Can I Microdose While On Antidepressants?
This needs a prescriber, not a blog. Combining classic psychedelics with lithium is a known red line, and interactions with SSRIs and SNRIs at microdose levels are largely unstudied. See, Can I Microdose If I'm Taking Antidepressants, and What Every Person on Psychiatric Medication Needs to Know Before Microdosing for the fuller picture, then talk to whoever manages your medication.
Who Should Not Microdose At All?
Anyone with a personal or family history of psychosis, schizophrenia, or bipolar disorder, anyone taking lithium, and anyone whose prescriber advises against it. These are the same exclusion criteria clinical trials use.
The Bottom Line
Microdosing means sub-perceptual doses, kept inside safe ranges (0.05 to 0.30 g dried cubensis, 5 to 20 µg LSD), usually on a fixed schedule like Fadiman's or the Stamets stack. The reported benefits are real to the people reporting them, but the strongest evidence so far, including the 2025 controlled data, suggests expectation plays a large role, and the practice carries legal and medical risks that rule it out for some people entirely. Start low, respect the contraindications, keep your own records, and talk to a qualified provider before you begin.
Want The Dosing And Protocol Details In One Place?
The Microdosing Protocol Guide lays out the ranges, schedules, and safety checks covered here in a single structured reference you can follow step by step. If you would rather start with the basics for free, the free mini-guide is a short introduction you can read in one sitting.
Educational content only. Not medical advice. Psilocybin and LSD are illegal in most jurisdictions; nothing here is encouragement to obtain or use a controlled substance.
